Regeneron Pharmaceuticals vs Medtronic

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (92 vs 90)
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
A92
Category Rank
#93 of 290
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
97
Perplexity
92
Gemini
99

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile
Medtronic logo

Medtronic

LeaderHealthcare Tech

Enterprise

World's largest medical device company with $32.4B FY2024 revenue; Hugo robotic surgery challenges Intuitive Surgical; MiniMed automated insulin system; Patient Monitoring spin-off 2024; NYSE: MDT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#126 of 290
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
85
Perplexity
97
Gemini
99

About

Medtronic plc is the world's largest medical device company, founded in 1949 by Earl Bakken and Palmer Hermundslie in a Minneapolis, Minnesota garage—where Bakken invented the first wearable external pacemaker—and now incorporated in Ireland with operational headquarters in Dublin, trading on NYSE (MDT). The company generated approximately $32.4 billion in revenues for fiscal year 2024 (ending April 26, 2024) under CEO Geoff Martha, spanning cardiovascular, neuroscience, surgical, and diabetes therapy technologies. Medtronic's 2015 acquisition of Covidien for $49.9 billion—at the time the largest medical device merger in history—added surgical instruments, patient monitoring, and respiratory interventions while enabling Irish incorporation that reduced the company's effective tax rate. In 2024, Medtronic announced the spin-off of its Patient Monitoring & Respiratory Interventions segment as an independent company (NewCo), sharpening focus on higher-margin, high-growth therapy areas.

Full profile

AI Visibility Head-to-Head

92
Overall Score
90
#93
Category Rank
#126
66
AI Consensus
53
stable
Trend
up
97
ChatGPT
85
92
Perplexity
97
99
Gemini
99
88
Claude
97
86
Grok
82

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Only Medtronic
Regeneron Pharmaceuticals is classified as company. Medtronic is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.